Naz Rahman
Stock Analyst at Maxim Group
(0.68)
# 2,907
Out of 4,479 analysts
34
Total ratings
25%
Success rate
-25.59%
Average return
Main Sectors:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRFX PainReform | Reiterates: Buy | $2 | $0.49 | +310.51% | 1 | Jun 26, 2024 | |
| ALIM Alimera Sciences | Downgrades: Hold | n/a | $5.52 | - | 2 | Jun 25, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $120 | $55.32 | +116.92% | 4 | Jun 4, 2024 | |
| VRPX Virpax Pharmaceuticals | Downgrades: Hold | n/a | $0.50 | - | 2 | May 22, 2024 | |
| PALI Palisade Bio | Reiterates: Buy | $23 | $4.30 | +423.26% | 6 | May 1, 2024 | |
| AGRX Agile Therapeutics | Downgrades: Hold | n/a | $1.42 | - | 3 | Mar 18, 2024 | |
| QNRX Quoin Pharmaceuticals | Maintains: Buy | $15 → $4 | $0.59 | +576.02% | 2 | Mar 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Downgrades: Hold | n/a | $471.25 | - | 1 | Jan 31, 2024 | |
| CING Cingulate | Downgrades: Hold | n/a | $0.34 | - | 3 | Dec 19, 2023 | |
| PTPI Petros Pharmaceuticals | Initiates: Buy | $4 | $0.43 | +823.79% | 1 | Dec 8, 2023 | |
| PCSA Processa Pharmaceuticals | Downgrades: Hold | n/a | $2.09 | - | 3 | Nov 17, 2023 | |
| AYTU Aytu BioPharma | Initiates: Buy | $5 | $2.85 | +75.44% | 1 | Aug 9, 2023 | |
| SCPH scPharmaceuticals | Maintains: Buy | $13 → $20 | $4.32 | +362.96% | 2 | May 11, 2023 | |
| ATNF 180 Life Sciences | Downgrades: Hold | n/a | $1.50 | - | 1 | May 9, 2022 | |
| NXGL NEXGEL | Initiates: Buy | $6 | $2.14 | +180.37% | 1 | Feb 25, 2022 | |
| NRSN NeuroSense Therapeutics | Initiates: Buy | $7 | $1.08 | +548.15% | 1 | Jan 7, 2022 |
PainReform
Jun 26, 2024
Reiterates: Buy
Price Target: $2
Current: $0.49
Upside: +310.51%
Alimera Sciences
Jun 25, 2024
Downgrades: Hold
Price Target: n/a
Current: $5.52
Upside: -
Viking Therapeutics
Jun 4, 2024
Reiterates: Buy
Price Target: $120
Current: $55.32
Upside: +116.92%
Virpax Pharmaceuticals
May 22, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.50
Upside: -
Palisade Bio
May 1, 2024
Reiterates: Buy
Price Target: $23
Current: $4.30
Upside: +423.26%
Agile Therapeutics
Mar 18, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.42
Upside: -
Quoin Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $15 → $4
Current: $0.59
Upside: +576.02%
Vertex Pharmaceuticals
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $471.25
Upside: -
Cingulate
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.34
Upside: -
Petros Pharmaceuticals
Dec 8, 2023
Initiates: Buy
Price Target: $4
Current: $0.43
Upside: +823.79%
Processa Pharmaceuticals
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.09
Upside: -
Aytu BioPharma
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $2.85
Upside: +75.44%
scPharmaceuticals
May 11, 2023
Maintains: Buy
Price Target: $13 → $20
Current: $4.32
Upside: +362.96%
180 Life Sciences
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.50
Upside: -
NEXGEL
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.14
Upside: +180.37%
NeuroSense Therapeutics
Jan 7, 2022
Initiates: Buy
Price Target: $7
Current: $1.08
Upside: +548.15%